Key TakeawaysNovartis on Thursday said it will seek label expansion of its prostate cancer treatment, Pluvicto, following a successful Phase 3 study.The drug maker said Pluvicto helped improve survival rates when patients received it prior to certain chemotherapies.Novartis explained that it planned to seek approval to expand Pluvicto's use in the second half of 2024.Novartis shares were up more than 2% in late trading Thursday. Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced ...

jetcityimage Following the Sandoz spin-off and Alcon sale, Novartis (NYSE:NVS) (OTCPK:NVSEF) has completed a big step in its transformation into a pure-play in innovative medicines (Fig 1). Novartis Pure-play Innovative Medicines Fig 1 Post Investor Day, we decided to raise our EPS forecast to CHF 7, arriving at a valuation of CHF 101.5 per share. Here at the Lab, we had mixed feelings about the company. On the one hand, Novartis is a quality business with a solid balance sheet and a strong R&D franchise. D ...

The most recent trading session ended with Novartis (NVS) standing at $94.41, reflecting a -1.52% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.72%. Elsewhere, the Dow saw a downswing of 1%, while the tech-heavy Nasdaq depreciated by 0.95%.Heading into today, shares of the drugmaker had lost 5.98% over the past month, lagging the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.The investment community will be paying close attention ...

There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time. Ideally, income-seeking investors want to avoid these situations. They prefer dividend-paying companies that can afford to raise their payouts regularly and aren't at risk of reducing or suspending their dividend programs.Let's look at one stock that can give income-seekers precisely what they want: Swiss pharma ...

Novartis (NVS) closed the latest trading day at $99.77, indicating a -1.58% change from the previous session's end. This move lagged the S&P 500's daily gain of 1.12%. Elsewhere, the Dow gained 0.61%, while the tech-heavy Nasdaq added 1.54%.Coming into today, shares of the drugmaker had gained 0.84% in the past month. In that same time, the Medical sector gained 2.49%, while the S&P 500 gained 2.06%.Investors will be eagerly watching for the performance of Novartis in its upcoming earnings disclosure. On th ...

In the latest trading session, Novartis (NVS) closed at $101.37, marking a +0.66% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.11%. Meanwhile, the Dow gained 0.12%, and the Nasdaq, a tech-heavy index, lost 0.41%.Prior to today's trading, shares of the drugmaker had lost 0.32% over the past month. This has lagged the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7% in that time.The investment community will be closely monitoring the performance of No ...

Novartis (NVS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned -4.1% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Novartis belongs, has gained 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumo ...

Novartis (NVS) ended the recent trading session at $102.22, demonstrating a -0.9% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.06%, and the technology-dominated Nasdaq saw a decrease of 0.55%.Coming into today, shares of the drugmaker had lost 4.27% in the past month. In that same time, the Medical sector gained 5.93%, while the S&P 500 gained 3.98%.Analysts and investors alike will be keeping a c ...

Novartis (NVS) announced that it will acquire Germany-based global biopharmaceutical company MorphoSys AG (MOR) to expand its oncology portfolio.Financial Terms of the AcquisitionNovartis will make a voluntary public takeover offer for all no-par value bearer shares of MorphoSys AG for €68 per share or an aggregate of €2.7 billion. The acquisition is expected to close in the first half of 2024.The transaction is contingent on customary closing conditions. This includes acceptance of the takeover offer by at ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...